Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer

NCT01784757 is registered in ClinicalTrials.gov with Orion Corporation, Orion Pharma as lead sponsor.

NCT NCT01784757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01784757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer
Lead sponsor
Orion Corporation, Orion Pharma
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2013
Completion date
December 31, 2020
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer